Trials / Completed
CompletedNCT03757130
Multiple Ascending Dose Study of AMG 598 in Adults With Obesity
A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 598 in Subjects With Obesity
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to assess the safety and tolerability of multiple doses of AMG 598 administered alone or in combination with liraglutide in adults with obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 598 | AMG 598 administered by subcutaneous injection |
| DRUG | Placebo | Placebo matching to AMG 598 administered by subcutaneous injection |
| DRUG | Liraglutide | Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5. |
Timeline
- Start date
- 2018-11-26
- Primary completion
- 2019-12-16
- Completion
- 2019-12-16
- First posted
- 2018-11-28
- Last updated
- 2023-09-14
- Results posted
- 2023-09-14
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03757130. Inclusion in this directory is not an endorsement.